We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+8.08%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.07B
AUM Growth
+$64.2M
Cap. Flow
+$82M
Cap. Flow %
7.68%
Top 10 Hldgs %
64.05%
Holding
53
New
4
Increased
9
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$22.6M
2
MDCO
Medicines Co
MDCO
+$21.8M
3
INSM icon
Insmed
INSM
+$16.1M
4
CHMA
Chiasma, Inc. Common Stock
CHMA
+$15.6M
5
ZYME icon
Zymeworks
ZYME
+$15.3M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$26M
2
ACER
Acer Therapeutics Inc
ACER
+$14.1M
3
QURE icon
uniQure
QURE
+$10.8M
4
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.55M
5
ZLAB icon
Zai Lab
ZLAB
+$2.11M

Sector Composition

Rank Sector Weight
1 Healthcare 94.71%
2 Materials 2.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.4B
$237M 22.23%
2,060,135
+13,303
+0.6% +$1.59M
CRNX icon
2
Crinetics Pharmaceuticals
CRNX
$8.88B
$84.4M 7.91%
3,375,169
– –
ARWR icon
3
Arrowhead Research
ARWR
$11.9B
$73.3M 6.87%
2,765,153
+436,678
+19% +$9.58M
TCDA
4
DELISTED
Tricida, Inc. Common Stock
TCDA
$56.2M 5.27%
1,424,525
+643,340
+82% +$22.6M
CDXS icon
5
Codexis
CDXS
$135M
$48.2M 4.52%
2,614,458
-4,493
-0.2% -$86.6K
INSM icon
6
Insmed
INSM
$22.6B
$44.8M 4.19%
1,748,174
+577,884
+49% +$16.1M
IOVA icon
7
Iovance Biotherapeutics
IOVA
$2.08B
$39.2M 3.68%
1,600,000
– –
SVA
8
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 3.58%
5,900,000
– –
ZYME icon
9
Zymeworks
ZYME
$1.65B
$32M 3%
1,453,467
+833,333
+134% +$15.3M
KALV
10
DELISTED
KalVista Pharmaceuticals
KALV
$30.1M 2.82%
1,359,149
– –
KDMN
11
DELISTED
Kadmon Holdings, Inc.
KDMN
$26M 2.43%
12,606,605
– –
MDCO
12
DELISTED
Medicines Co
MDCO
$24.4M 2.29%
+669,012
New +$21.8M
VYNE icon
13
VYNE Therapeutics
VYNE
$19.1M
$24M 2.25%
1,114
– –
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$24M 2.25%
233,045
-18,062
-7% -$1.41M
AMRS
15
DELISTED
Amyris Inc.
AMRS
$23.1M 2.17%
6,490,557
+914,772
+16% +$3.6M
QTTB icon
16
Q32 Bio
QTTB
$461M
$22.7M 2.13%
64,430
– –
EIGR
17
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$19M 1.78%
59,709
– –
ORTX
18
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$18.4M 1.72%
131,208
+83,047
+172% +$14.6M
CHMA
19
DELISTED
Chiasma, Inc. Common Stock
CHMA
$17.8M 1.66%
+2,377,213
New +$15.6M
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
$15.4M 1.45%
2,154,934
+98,934
+5% +$1.12M
LITS
21
Lite Strategy Inc
LITS
$33.4M
$14.2M 1.33%
284,070
-4,835
-2% -$284K
XENE icon
22
Xenon Pharmaceuticals
XENE
$6.28B
$13.9M 1.3%
1,405,476
– –
AUPH icon
23
Aurinia Pharmaceuticals
AUPH
$1.92B
$12.6M 1.18%
1,913,623
+700,333
+58% +$4.46M
SLNO
24
DELISTED
Soleno Therapeutics
SLNO
$12M 1.12%
284,597
-6,049
-2% -$209K
RCKT icon
25
Rocket Pharmaceuticals
RCKT
$348M
$11.8M 1.11%
+786,712
New +$13.7M
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return

Vivo Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Vivo Capital held 53 positions worth $1.07B, up 6.4% from $1B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Vivo Capital deployed $82M of net new capital in Q2 2019, opening 4 new positions and adding to 9 existing holdings. Its largest new stake was Medicines Co: 669,012 shares worth $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Genocea Biosciences, Inc., an estimated $1.83M trimmed.

  • Vivo Capital's largest Q2 2019 buy was Medicines Co: 669,012 shares worth $24.4M.
  • Vivo Capital added most to Tricida, Inc. Common Stock in Q2 2019, an estimated $22.6M increase.
  • Vivo Capital's biggest Q2 2019 reduction was Genocea Biosciences, Inc., cutting an estimated $1.83M.
  • Vivo Capital fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019, selling an estimated $26M.
  • Vivo Capital's ten largest holdings make up 64% of its $1.07B portfolio in Q2 2019.
  • Vivo Capital opened 4 new positions and closed 7 in Q2 2019.
  • Vivo Capital's portfolio value rose 6.4% quarter-over-quarter to $1.07B.

Based on Vivo Capital's 13F filing for Q2 2019, filed 13 Aug 2019.